The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 February 2026•

1 min read

TD Cowen Raises BDX Price Target to $189, Maintains Hold After Strong Q1 Beat

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

TD Cowen has adjusted its outlook for Becton, Dickinson and Company (NYSE:BDX), raising its price target to $189 from $183 while reiterating a "hold" rating. This revision follows Becton, Dickinson's robust first-quarter performance, which significantly surpassed analyst expectations. The medical technology firm reported earnings per share of $2.91, exceeding the anticipated $2.81, alongside revenues of $5.25 billion. These figures indicate strong operational execution and market demand for its products. Furthermore, BDX demonstrated proactive capital management, announcing a $10 million share buyback program and tender offers to repurchase up to $1.6 billion in debt. The mixed analyst sentiment reflects the positive financial results balanced against a cautious long-term outlook.